Company Rings Opening Bell to Celebrate
Closure of Business Combination and Begins Journey as a Public
Company; Shares trade under "BDMD" Ticker
FORT
MILL, S.C., Oct. 9, 2024
/PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ:
BDMD) ("Baird Medical" or the "Company"), a leading microwave
ablation ("MWA") medical device developer and provider
in China which has recently expanded into the U.S. market
following its receipt of US FDA 510(k) clearances, today
announced a successful listing in the U.S. on the Nasdaq
exchange. With shares trading under the ticker symbol "BDMD" on
October 2, 2024, this important
milestone marks the successful closure of its business combination
and signifies its journey as a public company. In honor of the
occasion, Wenyuan Wu, Baird
Medical's Co-Founder, rang the Opening Bell together with other
executives, partners and friends of the company.
"Becoming a public company in the
United States is both a critical juncture for us and
signifies our shift toward addressing unmet needs in the market,"
said Wenyuan Wu, Baird Medical's
Co-Founder. "Our technology benefits patient and physician alike in
enabling safer, more efficient and attractive procedures for
thyroid care. We are delighted to fill this pressing need as we
grow our business."
The Nasdaq listing comes as the Company expands its footprint in
the U.S. market following recent FDA clearance for its minimally
invasive microwave ablation technology, which offers a promising
alternative to thyroidectomy for patients with benign thyroid
tumors. Currently, 150,000 thyroidectomies are performed in
the U.S. annually.
About Baird Medical
Established in 2012 and headquartered in Guangzhou, China, Baird Medical is a leading
microwave ablation ("MWA") medical device manufacturer and provider
in China and a recent entrant to
the United States market. Baird
Medical's proprietary medical devices are used for the treatment of
benign and malignant tumors including thyroid nodules, liver
cancer, lung cancer and breast lumps. Baird Medical is the first
company to obtain a Class III medical devices registration
certificate for MWA medical devices specifically indicated for
thyroid nodules in China. For more
information, please visit http://www.bairdmed.com/.
Contacts
Investor Relations
Robin Yang, Partner
ICR, LLC
Phone: +1 (646) 308-1475
Email: BairdMedical.IR@icrinc.com
Public Relations
Brad Burgess, Senior Vice
President
ICR, LLC
Phone: +1 (646) 588-0383
Email: BairdMedical.PR@icrinc.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/baird-medical-lists-in-the-us-on-the-nasdaq-exchange-302271491.html
SOURCE Baird Medical Investment Holdings Ltd.